银屑病生物制剂治疗应答相关临床特征:一项Meta分析
观察性研究显示,较高年龄、既往生物制剂暴露、较高BMI、既往吸烟和当前吸烟与6个月时达到PASI 90负相关;随机对照试验中仅BMI≥30与3个月时PASI 90负相关。
要点
- 吸烟、既往生物制剂暴露、较高年龄和高BMI与生物制剂应答较差相关。
- 随机对照试验中仅BMI≥30与3个月PASI 90负相关。
- 不同生物制剂间临床特征是否影响应答仍不明确。
核心结论
- 观察性研究显示,吸烟或既往吸烟、既往生物制剂暴露、较高年龄或较高BMI的银屑病患者对生物制剂应答较差。
- 不同生物制剂间这些临床特征是否影响应答仍不明确。
研究设计与样本
- 系统检索PubMed、Embase和Web of Science自建库至2022年4月,纳入报告批准剂量生物制剂治疗后12、26和/或52周PASI 75或PASI 90的观察性研究和随机对照试验。
主要发现
- 观察性研究中,较高年龄与6个月PASI 90负相关(OR 0.99,95%CI 0.98-1.00)。
- 观察性研究中,既往生物制剂暴露与6个月PASI 90负相关(OR 0.44,95%CI 0.29-0.67)。
- 观察性研究中,较高BMI与6个月PASI 90负相关(OR 0.96,95%CI 0.94-0.99)。
- 观察性研究中,既往吸烟(OR 0.81,95%CI 0.67-0.98)和当前吸烟(OR 0.78,95%CI 0.66-0.91)与6个月PASI 90负相关。
- 随机对照试验中,BMI≥30与3个月PASI 90负相关(OR 0.57,95%CI 0.48-0.66)。
临床怎么用
- 对吸烟、既往生物制剂暴露、较高年龄或高BMI的银屑病患者,可预期生物制剂应答可能较差。
- 临床决策时可考虑这些特征,但不同生物制剂间的差异尚不明确。
局限性
- 不同生物制剂间临床特征对治疗应答的影响是否不同尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical characteristics associated with treatment response to biologics in patients with psoriasis have never been systematically investigated. OBJECTIVE: To evaluate the association between patient clinical characteristics and the effectiveness of biologics in treating psoriasis. DATA SOURCES: PubMed, Embase, and Web of Science were searched from their inception through April 2022. Studies in English language that reported response to biologic treatment at approved doses in patients with psoriasis in relation to their clinical characteristics were included. In addition, eligible studies were identified through a search of the reference lists of the included studies. STUDY SELECTION: We only included studies that reported treatment outcomes as Psoriasis Area and Severity Index (PASI) 75 or PASI 90 after 12, 26, and/or 52 weeks of treatment. Both observational studies and randomized clinical trials (RCTs) were considered. Two independent authors conducted the screening process, and 107 studies were assessed for eligibility. DATA EXTRACTION AND SYNTHESIS: The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines were followed. Relevant data were extracted independently by 2 authors. Data were pooled using random-effects models. RCTs and observational studies were pooled in separate analyses. Data were analyzed from June 1, 2023, to August 1, 2023. MAIN OUTCOMES AND MEASURES: The primary outcome was PASI 90 at 26 weeks (6 months). Before data collection began, an investigation of the association between the main (and secondary) outcomes and several clinical characteristics was planned. RESULTS: Overall, 40 studies with a total of 21 438 patients were included. Older age (odds ratio [OR], 0.99; 95% CI, 0.98-1.00), previous exposure to biologics (OR, 0.44; 95% CI, 0.29-0.67), higher body mass index (BMI) (OR, 0.96; 95% CI, 0.94-0.99), previous smoking (OR, 0.81; 95% CI, 0.67-0.98), and current smoking (OR, 0.78; 95% CI, 0.66-0.91) were negatively associated with achieving PASI 90 at 6 months in observational studies. In RCTs, only BMI of 30 or higher was negatively associated with treatment response (PASI 90 at 3 months: OR, 0.57; 95% CI, 0.48-0.66). CONCLUSIONS AND RELEVANCE: This meta-analysis found that patients with psoriasis who smoke or have a history of smoking, as well as those with previous exposure to biologics, older age, or higher BMI, exhibited poorer response to biologics in observational studies. However, it remains unclear whether these clinical characteristics influence treatment response differently for the different biologics available for psoriasis.
引用
- Hjort G, Schwarz CW, Skov L, et al. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis. JAMA Dermatol. 2024. PMID: 38888917. doi:10.1001/jamadermatol.2024.1677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。